Proteomic differences among patients with heart failure taking furosemide or torsemide.
Proteomic differences among patients with heart failure taking furosemide or torsemide.
复制标题
心力衰竭患者服用速尿或扭转的患者之间的蛋白质组学差异。
DOI：
10.1002/clc.23733
复制
发表时间：
2022-03
影响因子：
2.7
通讯作者：
deFilippi C
中科院分区：
文献类型：
--
作者：
Cooper LB;Bruce S;Psotka M;Mentz R;Bell R;Seliger SL;O'Connor C;deFilippi C
袢利尿剂常用于心力衰竭（HF）患者，但尚不清楚一种袢利尿剂是否具有临床上级优势。生物标志物和蛋白质组学提供了不同的袢利尿剂如何不同地影响结果的见解。从服用托拉塞米或呋塞米>30天的HF门诊患者中收集血液和尿液。使用Olink Cardiovascular III和炎症组评估了心脏、肾脏和炎症生物标志物和可溶性蛋白组的差异。在78例受试者中，55例（71%）接受呋塞米治疗，23例（29%）接受托拉塞米治疗，25例提供了尿液样本（15例接受呋塞米治疗，10例接受托拉塞米治疗）。服用托拉塞米的患者年龄较大（68 vs 64岁），平均eGFR较低（46 vs 54 ml/min/1.73 m2），女性（39% vs 24%）和黑人（43% vs 27%）比例较高。在血浆中，各组之间的hs-cTnT、NT-proBNP和hsCRP水平无显著差异。在尿液中，尿白蛋白、β-2M和NGAL存在显著差异，托拉塞米治疗患者的水平更高。在Olink板中检测的184种蛋白质中，血浆中有156种（85%）在服用托拉塞米的患者中较高，但在纠正错误发现后无显著差异。我们发现，在使用不同袢利尿剂的HF患者中，尿液生物标志物存在差异，但血浆生物标志物差异不大。Olink技术可以检测来自多个生物领域的血浆蛋白水平差异。这些发现提高了在适当的动力研究中确定每种利尿剂作用机制差异的重要性。
Loop diuretics are commonly used for patients with heart failure (HF) but it remains unknown if one loop diuretic is clinically superior. Biomarkers and proteomics provide insight to how different loop diuretics may differentially affect outcomes. Blood and urine were collected from outpatients with HF who were taking torsemide or furosemide for >30 days. Differences were assessed in cardiac, renal, and inflammatory biomarkers and soluble protein panels using the Olink Cardiovascular III and inflammation panels. Of 78 subjects, 55 (71%) were treated with furosemide and 23 (29%) with torsemide, and 25 provided a urine sample (15 treated with furosemide, 10 with torsemide). Patients taking torsemide were older (68 vs 64 years) with a lower mean eGFR (46 vs 54 ml/min/1.73 m2), a higher proportion were women (39% vs 24%) and Black (43% vs 27%). In plasma, levels of hs‐cTnT, NT‐proBNP, and hsCRP were not significantly different between groups. In urine, there were significant differences in urinary albumin, β‐2M, and NGAL, with higher levels in the torsemide‐treated patients. Of 184 proteins testing in Olink panels, in plasma, 156 (85%) were higher in patients taking torsemide but none were significantly different after correcting for false discovery. We show differences in urinary biomarkers but few differences in plasma biomarkers among HF patients on different loop diuretics. Olink technology can detect differences in plasma protein levels from multiple biologic domains. These findings raise the importance of defining differences in mechanisms of action of each diuretic in an appropriately powered study.
登录
查看更多内容
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y
影响因子：
5.9
作者：
Gottlieb, SS;Khatta, M;Kramer, WG
通讯作者：
Kramer, WG
影响因子：
2.8
作者：
Abraham, Bishoy;Megaly, Michael;Sharma, Rajaninder
通讯作者：
Sharma, Rajaninder
影响因子：
3
作者：
Mentz, Robert J.;Buggey, Jonathan;Velazquez, Eric J.
通讯作者：
Velazquez, Eric J.
影响因子：
3.8
作者：
Bettencourt P;Ferreira-Coimbra J;Rodrigues P;Marques P;Moreira H;Pinto MJ;Guimarães JT;Lourenço P
通讯作者：
Lourenço P